Autoinhibition of c-Abl

Cell

Volumn 108, Issue 2, 2002, Pages 247-259

  Pluk, Helma ^a   Dorey, Karel ^a   Superti Furga, Giulio ^a,b  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; AUTOREGULATION; CARCINOGENICITY; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME REGULATION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION;

EID: 0037169351     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)00623-2     Document Type: Article

References (48)

1. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin
2. An intramolecular SH3-domain interaction regulates c-Abl activity
3. A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK
4. TATA box mutations in the Schizosaccharomyces pombe nmt1 promoter affect transcription efficiency but not the transcription start point or thiamine repressibility
5. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines
6. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation
7. Regulation of human c-Abl tyrosine kinase activity in Xenopus oocytes and acceleration of progesterone-induced G2/M transition by oncogenic forms
8. Phosphorylation and structure-based functional studies reveal multiple roles for the activation loop of the c-Abl tyrosine kinase
9. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
10. Deletion of an N-terminal regulatory domain of the c-Abl tyrosine kinase activates its oncogenic potential
11. Oncogenic activation of c-Abl by mutation within its last exon
12. Oligomerization of the Abl tyrosine kinase by the Ets protein TEL in human leukemia
13. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src
14. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
15. Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice
16. N-terminal mutations activate the leukemogenic potential of the myristylated form of c-abl
17. Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk
18. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase
19. New-age drug meets resistance
20. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
21. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
22. High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides
23. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor
24. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence
25. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
26. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF
27. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
28. Signal transduction by wild-type and leukemogenic Abl proteins
29. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites
30. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context
31. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation
32. Rac is required for v-Abl tyrosine kinase to activate mitogenesis
33. The bcr-abl gene in chronic myelogenous leukemia
34. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
35. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene
36. Structures of Src-family tyrosine kinases
37. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization
38. Structure-function relationships in Src family and related protein tyrosine kinases
39. Csk inhibition of Src activity requires both the SH2 and SH3 domains of Src
40. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase
41. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
42. Cycling, stressed-out and nervous: Cellular functions of c-Abl
43. The COOH-terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity
44. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
45. Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe
46. Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids
47. Regulation of cell death by the abl tyrosine kinase
48. Inhibition of c-Abl tyrosine kinase by filamentous-actin